WHO Prequalification of In Vitro Diagnostics PUBLIC REPORT

Product: ONE STEP Malaria (Pf/Pv) Tri-line Test WHO reference number: PQDx 0627-017-00

ONE STEP Malaria (Pf/Pv) Tri-line Test with product codes ITPW11009-TC25 and ITPW11009-TC40 manufactured by InTec Products, Inc., Rest of World regulatory, was accepted for the WHO list of prequalified in vitro diagnostics and was listed on 28 May 2024.

Summary of WHO Prequalification Assessment for One Step Malaria (Pf/Pv) Tri-Line Test

	Date	Outcome
Prequalification listing	28 May 2024	listed
Dossier assessment	12 April 2024	MR
Site inspection of quality	11 to 13 October 2023	MR
management system		
Product performance	Quarter 3 2021	MR
evaluation		

MR: Meets Requirements

Intended use

According to the intended use claim from InTec Products, Inc., "One Step Malaria (Pf/Pv) Tri-line Test is a colloidal gold, two site sandwich immunoassay utilizing whole blood (venous and fingerstick) for the detection of Pf specific histidine rich protein-II (Pf HRP-II) and Pv specific pLDH. This rapid test can be used as an aid in the diagnosis and differentiation of malaria infections caused by P.falciparum and P.vivax for symptomatic patients1, including adults (including pregnant women) and children. This test is intended for professional use by laboratory professionals, trained healthcare workers or trained lay providers in laboratory and non-laboratory settings."

Assay description

According to the claim of assay description from InTec Products, Inc, "Colloid gold conjugated-Anti-HRP-II(a) and colloid gold conjugated-Anti-pLDH(a) are pre-applied in the reaction pad. Anti-HRP-II(b) is pre-coated in the Pf band region of the membrane. Anti-pLDH(b) is pre-coated in the Pv band region of the membrane. After the buffer is added, red blood cells will be lysed.

For Pf positive specimens, colloid gold conjugated-Anti-HRP-II(a) will react with HRP-II released from red blood cells and form a colloid gold conjugated-Anti-HRP-II(a)-HRP-II

complex. The complex will migrate through the test strip and be captured by Anti-HRP-II(b) pre-coated in the Pf band region, forming a Pf band.

For Pv-positive specimens, colloid gold conjugated-Anti-pLDH(a) will react with pLDH released from red blood cells and form a colloid gold conjugated-Anti-pLDH(a)-pLDH complex. The complex will migrate through the test strip and be captured by Anti-pLDH(b) pre-coated in the Pv band region, forming a Pv band.

For Pf and Pv co-infected specimens, two kinds of complexes above will form. The complexes will migrate through the test strip and be captured by correlated antibodies pre-coated in the Pf band region and Pv band region, forming a Pf band and a Pv band.

A negative specimen will not produce a Pf band or Pv due to the absence of a colloidal gold conjugate/plasmodium antigen complex. To ensure assay validity, a control band in the control band region will appear at the end of the test procedure regardless of the test result. Only when the control band appears the assay is valid."

Component	25 Tests/Kit (T/K)	40 T/K
	(ITPW11009-TC25)	(ITPW11009-TC40)
Cassette	1 x 25 pieces	1 x 40 pieces
Dropper	1 x 25 pieces	1 x 40 pieces
Buffer bottle	2mL x 3 bottles	2mL x 4 bottles
Lancet	1 x 25 pieces	1 x 40 pieces
Alcohol swab	1 x 25 pieces	1 x 40 pieces
Instructions for use	1 x 1 piece	1 x 1 piece

Test kit contents

Items required but not provided:

- Timer or stopwatch.
- Blood sampling tools (sterile gauze pad, venous puncture device, collection tube with EDTA/heparin sodium/sodium citrate for whole blood or plasma, collection tube with no anticoagulant for serum.)
- Biohazard waste bin and sharps bin.
- Disposable gloves.
- A calibrated precision pipette and applicable pipette tips.

Storage

The test kit should be stored at 2-40 °C.

Shelf-life upon manufacture

24 months.

Warnings/limitations

Please refer to the current version of the manufacturer's instructions for use attached to this public report.

Prioritization for Prequalification Assessment

Based on the established criteria, the One Step Malaria (Pf/Pv) Tri-Line Test was given priority for WHO prequalification assessment.

Dossier assessment

InTec Products, Inc. submitted a product dossier for One Step Malaria (Pf/Pv) Tri-Line Test as per the "Instructions for compilation of a product dossier" (PQDx_018). The information (data and documentation) submitted in the product dossier was reviewed by WHO staff and external technical experts (assessors) appointed by WHO. The manufacturer's responses to the nonconformities found during dossier screening and assessment findings were accepted on 12 April 2024.

Commitments for prequalification

- 1. The manufacturer must submit additional information regarding the formulation and composition. At the time of publication of this Public Report, the information was provided and is under review.
- 2. The manufacturer must submit additional information regarding the specimen type. At the time of publication of this Public Report, the information was provided and is under review.
- 3. The manufacturer must submit additional information regarding analytical specificity. At the time of publication of this Public Report, the information was provided and is under review.
- 4. The manufacturer must submit additional information regarding the clinical evaluation. At the time of publication of this Public Report, the information was provided and is under review.

Based on the product dossier screening and assessment findings, the product dossier for the ONE STEP Malaria (Pf/Pv) Tri-line Test meets WHO prequalification requirements.

Manufacturing site inspection

An onsite inspection of InTec Products, Inc. at 332 Xinguang Rd, Xinyang IND AREA, Haicang, Xiamen 361011, China, was conducted from 11 to 13 October 2023. At the time of considering the product application for Prequalification, the Manufacturer of the product had a well-established quality management system and manufacturing practices in place

that would support the manufacture of a product of consistent quality. Routine inspections of the Manufacturing site will be conducted with copies of the WHO Public Inspection Report (WHOPIR) published on the WHO Prequalification web page as per Resolution WHA57.14 of the World Health Assembly. Note that a WHOPIR reflects the information on the most current assessment performed at a manufacturing site for in vitro diagnostic products and summarises the assessment findings.

https://extranet.who.int/pqweb/vitro-diagnostics/who-public-inspection-reports

All published WHOPIRs are with the agreement of the manufacturer.

Based on the site inspection and corrective action plan review, the quality management system for the ONE STEP Malaria (Pf/Pv) Tri-line Test meets WHO prequalification requirements.

Product performance evaluation

ONE STEP Malaria (Pf/Pv) Tri-line Test was evaluated in the 3rd quarter of 2021 at Centers of Disease Control and Prevention on behalf of WHO according to protocol PQDx_317, version 2.1. From this evaluation, we drew the following conclusions.

ONE STEP Malaria (Pf/Pv) Tri-line Test was evaluated against a *Plasmodium falciparum* cultured line panel, *P. falciparum* wild-type parasite panel, *P. vivax* wild-type parasite panel and a *P. falciparum* and *P.vivax* negative panel.

Performance characteristics	Performance characteristics							
	P. falciparum P. vivax							
Panel detection score at 200 parasites/μL (N _{Pf} =100) (N _{Pv} =35)	93/100, 93.0%	35/35, 100%						
False positive results %	Negative specimens: 0/200, 09	%						
	Of which, clean negative specimens: 0/104, 0.0%							
Invalid rate %	0/1010, 0.0%							
(N= 1010)								
Inter-reader variability %	HRP-2 test line: 1.0% (10/1010)							
(N= 1010)	Pv-pLDH test line: 0.3% (3/101	0)						
The lowest concentration of HRP-2 was detected using the 1 st WHO	HRP-2 test line: 31.3 IU/mL for both lots							
International standard for Pf antigens (NIBSC code: 16/376)								

Operational characteristics and ease of use

This assay does not require laboratory equipment and can be performed in laboratories with limited facilities or in non-laboratory settings.

The assay was found easy to use by the operators performing the evaluation.

Key operational characteristics	
Specimen types and volume	5 μ L of capillary or venous whole blood
Number of steps*	2 steps in total
	1 step with specimen transfer device (precision pipette
	was used during the evaluation)
Time to result	15 minutes
Endpoint stability (interval)	5 minutes (the test can be read between 15 and 20 minutes after addition of diluent)
Internal QC	Yes, reagent addition control

* Definition: each action required to obtain a result (excluding specimen collection, device preparation – opening the pouch), e.g. for RDTs: add specimen, add buffer (2 steps).

Based on these results, the performance evaluation for ONE STEP Malaria (Pf/Pv) Tri-line Test meets the WHO prequalification requirements.

Labelling

- 1. Labels
- 2. Instructions for use

1. Labels

1.1. 25 T/K, product code ITPW11009-TC25







InTec PRODUCTS, INC. 332 Xinguang Road, Xinyang Industrial Area, Haicang, 361022, Xiamen, Fujian, P.R.China

Tel: +86 592 6807188 Website: www.intecasi.com Email: intecproducts@asintec.com











1.2. 40 T/K, product code ITPW11009-TC40

ONE STEP Malaria (Pf/Pv) Tri-lineTest

Malaria Antigen Pf/Pv (HRP2/pLDH) RDT

Malaria

Content

40 Cassettes 40 Droppers 4 Buffer bottles 40 Lancets 40 Alcohol swabs 1 Instructions for use

Inlec®

Required but not provided

Timer or stopwatch Blood sampling tools Biohazard waste bin Sharps bin Disposable gloves



01.05.11.089-240402







a Piul













2. Instructions for use¹

 $^{^1}$ English version of the IFU was the one that was assessed by WHO. The manufacturer is responsible for ensuring correct translation into other languages.

Me^C InTec PRODUCTS, INC.

REF ITPW11009-TC25 ITPW11009-TC40 01.05.14.079-240507

One Step Malaria (Pf/Pv) Tri-line Test

FOR IN VITRO DIAGNOSTIC USE ONLY.

Please read this instructions for use carefully prior to use and strictly follow the instructions. \Box_{i} Reliability of the assay cannot be guaranteed if there are any deviations from the instructions for use.

Clinical significance

Malaria is a serious, sometimes fatal, parasitic disease, widespread in the tropical and subtropical regions (mainly Africa, South America, and Southeast Asia). It is characterized by fever with chills, anemia and is caused by Plasmodium parasite that is transmitted to people through the bites of infected female Anopheles mosquitoes.

Among several parasitic Plasmodium species that cause malaria in humans (i.e., P. falciparum, P. vivax, P. malariae, P. ovale, and P. knowlesi), P. falciparum (Pf) and P. vivax (Pv) are two pathogens posing the greatest threat as they are the deadliest or most prevalent.

Intended use

One Step Malaria (Pf/Pv) Tri-line Test is a colloidal gold, two site sandwich immunoassay utilizing whole blood (venous and fingerstick) for the detection of Pf specific histidine rich protein-II (Pf HRP-II) and Pv specific pLDH. This rapid test can be used as an aid in the diagnosis and differentiation of malaria infections caused by P.falciparum and P.vivax for symptomatic patients¹, including adult (including pregnant women) and children. This test is intended for professional use by laboratory professionals, trained healthcare workers or trained lay providers in laboratory and non-laboratory settings.

Summarv

One Step Malaria (Pf/Pv) Tri-line Test is based on immunochromatography, and used for HRP-II/pLDH detection in human whole blood (venous and fingerstick)²⁻³. It is a simple, visual qualitative test that detects Pf HRP-II and Pv pLDH in human whole blood, and presents the result within 20 minutes³.

Test principle⁴

Colloid gold conjugated-Anti-HRP-II(a) and colloid gold conjugated-Anti-pLDH(a) are pre-applied in the reaction pad. Anti-HRP-II(b) is pre-coated in the Pf band region of the membrane. Anti-pLDH(b) is pre-coated in the Pv band region of the membrane. After the buffer is added, red blood cells will be lysed. For Pf positive specimens, colloid gold conjugated-Anti-HRP-II(a) will react with HRP-II released from red blood cells and form a colloid gold conjugated-Anti-HRP-II(a)-HRP-II complex. The complex will migrate through the test strip and be captured by Anti-HRP-II(b) pre-coated in the Pf band region, forming a Pf band. For Pv positive specimens, colloid gold conjugated-Anti-pLDH(a) will react with pLDH released from red blood cells and form a colloid gold conjugated-Anti-pLDH(a)-pLDH complex. The complex will migrate through the test strip and be captured by Anti-pLDH(b) pre-coated in the Pv band region, forming a Pv band. For Pf and Pv co-infected specimens, two kinds of complexes above will form. The complexes will migrate through the test strip and be captured by correlated antibodies pre-coated in the Pf band region and Pv band region, forming a Pf band and a Pv band.

A negative specimen will not produce a Pf band or Pv due to the absence of a colloidal gold conjugate/plasmodium antigen complex. To ensure assay validity, a control band in the control band region will appear at the end of the test procedure regardless of the test result.

Only when the control band appears the assay is valid.

Storage conditions and stability

One Step Malaria (Pf/Pv) Tri-line Test shall be stored at 2-40°C. Test cassette should be used immediately upon opening the foil pouch. Buffer should be and used within 8 weeks after opening.

A Warnings and precautions

The warnings and precautions are included, but not limited to the following:

• This product is for in vitro diagnosis of the infection of Pf and/or Pv only, and other diseases cannot be analyzed with any component of this kit

- Wear gloves during the entire testing process.
- · Do not use expired reagents or test cassettes.
- Do not use accessories if the seal or package is broken. 🛞
- Do not use test cassette if the foil pouch is damaged or the seal is broken. (6)
- Do not use the provided lancet if the cap is already pulled off before use. 🛞
- Do not reuse the accessories. All the accessories are for single use. (2)
- Do not reuse the test cassette. Each cassette enclosed in a foil pouch is only for single use. (2)
- · Do not suck buffer or specimen by mouth.
- Do not eat or smoke while handling specimens.
- Do not store specimen in dropper, it is only used for specimen collection.
- Do not use pooled specimens or specimens other than specified (i.e. saliva, urine).
- Do not interchange reagents among kits of different batch number or even products.
- Do not perform the test under environment which leads to rapid evaporation (e.g. close to a running fan or air conditioner)
- · Ensure the specimen is added correctly prior to the addition of buffer.
- · Avoid contact between the "S" well of cassette and buffer bottle to prevent contamination of buffer.

- Clean and disinfect all the areas that may be contaminated by spills of specimens or reagents with appropriate disinfectant
- · Decontaminate and dispose of all specimens, reagents, accessories and other potentially contaminated materials as infectious wastes in a biohazard container. Used lancet should be disposed of in a sharps bin. · Operate the test at conditions that are both >40°C and >70% relative humidity (RH) might lead to incorrect results.

 Sample buffer contains 0.3% Triton X-100 and 0.01% sodium azide. If contact with buffer to the eyes and/or skin, wash affected area with soap and water immediately. Do not dispose buffer enter drains, and offer surplus solutions to a licensed disposal company (dispose of contents/container to an approved waste disposal plant).

Reagents and materials provided

Table 1 Reagents and materials provided

Components	25 tests (ITPW11009-TC25)	40 tests (ITPW11009-TC40)	
Cassette	1 x 25 pieces	1 x 40 pieces	
Dropper	1 x 25 pieces	1 x 40 pieces	
Buffer bottle	2mL x 3 bottles	2mL x 4 bottles	
Lancet	1 x 25 pieces	1 x 40 pieces	
Alcohol swab	1 x 25 pieces	1 x 40 pieces	
Instructions for use	1 x 1 piece	1 x 1 piece	

Materials required but not provided

Timer or stopwatch

- · Blood sampling tools (sterile gauze pad, venous puncture device, collection tube with EDTA/heparin
- sodium/sodium citrate for whole blood or plasma, collection tube with no anticoagulant for serum.)
- · Biohazard waste bin and sharps bin
- Disposable gloves
- A calibrated precision pipette and applicable pipette tips

Preparation

1. Unseal the foil pouches. The components are as below:



Dropper Cassette



I. Fingerstick whole blood

4. Clean the finger Twist the lancet cap for over 180 with alcohol swat and leave it to dry and remove it





9. Touch the dropper tip 10. Add 3 drops on the pad of "S" well, to add all the blood collected

of buffer into "D wall immediately

6. Place the lancet

firmly on side of finger (avoid callus)

to trigger it



Gently press around

the bleeding point Wipe away the first

drop of blood.

11. Wait and interpret the result betweer 15-20 minutes



II. Venous whole blood



Specimen collection and storage

Negative result

Fingerstick whole blood

1) Rub the target finger (middle or ring finger) to stimulate blood flow, and avoid calloused areas of the finger. Clean the finger with an alcohol swab (Figure I.4) and leave it to dry.

Invalid result

- 2) Prick the finger with the provided lancet: (a) Twist clockwise the protective cap and remove it, see Figure I.5 for details. (b) Place the lancet firmly on the finger to trigger it, see Figure I.6 for details.
- 3) Gently press the bleeding point (avoid excessive bleeding). Wipe away the first drop of blood with a sterile gauze pad (Figure I.7). Allow a new drop of blood to form.
- 4) Transfer the blood specimen with the dropper provided. Gently squeeze the bulb of the dropper, touch the blood, and gently release the bulb to draw up the blood (Figure I.8).
- Note: The fingerstick blood should be tested immediately after collection.

Venous whole blood

Collect whole blood specimen into a collection tube (with specified anticoagulant, namely EDTA, heparin sodium or sodium citrate) according to standard venous blood sampling process. Then gently mix the venous blood collection tube by inverting the specimen to make it homogenous for sampling. Other anticoagulants may lead to incorrect results.

Notes:

- Venous whole blood specimens can be stored at 2-8°C for up to 7 days if not tested immediately. Store at -18°C or below for 30 months. Frozen specimens shall be equilibrated to room temperature (10-30°C) before testing. Multiple freeze-thaw cycles should be avoided (3 times at most).
- · Avoid using hyperlipidemia or excessively aged specimens.

Test procedure

- 1. Do not open the pouch until ready to perform a test. Use the test under low environment humidity (RH≤ 70%) within 1 hour
- 2. Equilibrate all reagents and specimens to room temperature (10-30°C) before use.
- 3. Unseal the foil pouch and put the cassette on a flat, clean and dry surface.
- 4. Mark the sample ID number on test cassette.
- 5. Gently squeeze and release the bulb of the dropper to collect blood until reaching 5µL mark (or 5µL by the transfer pipette) and touch the dropper tip on the pad of "S" well.
- 6. Then add 3 drops of lysis buffer into "D" well and start the timer immediately.
- 7. Wait for at least 15 minutes (and 20 minutes at most) to interpret the result.

▲ Caution:

- Always apply specimen with a new and clean dropper or pipette tip to avoid cross contamination.
- Negative results cannot rule out the possibility of the exposure to or the infection with of Pf and/or Pv.

Result interpretation

Pf positive: Purplish red bands appear at both the Pf band area (even though very faint) and the control band area indicates a positive result

Pv positive: Purplish red bands appear at both the Pv band area (even though very faint) and the control band area indicates a positive result.

Pf and Pv co-infected: Purplish red bands appear at Pf band area (even though very faint), Pv band area (even though very faint) and the control band area indicates a positive result.

Negative: Purplish red band only appears on control band area indicates a negative result.

Invalid 1: A purplish red band appears only at the Pf band area of the cassette. Repeat the test. Contact the supplier if the control band remains invisible. 3

Invalid 2: A purplish red band appears only at the Pv band area of the cassette. Repeat the test. Contact the supplier if the control band remains invisible.

Invalid 3: A purplish red band appears at both the Pf band area and the Pv band area but not the control band area of the cassette. Repeat the test. Contact the supplier if the control band remains invisible.

Invalid 4: Purplish red band appears at none of the three band areas (Pf band area and Pv band area and control band area) of the cassette. Repeat the test. Contact the supplier if the control band remains invisible.

Performance characteristics

The performance characteristics of One Step Malaria (Pf/Pv) Tri-line Test was established based on external clinical evaluations and internal studies. Concluded from the study results, the analytical performance and clinical performance were summarized as below:

1. Potential interfering substances

The following listed 25 potentially interfering substances have no impact on the test result of One Step Malaria (Pf/Pv) Tri-line Test. Although no interference observed in the study, the possibility cannot be excluded completely.

No.	Type of Specimen	Potential Interfering Substance	Sample Quantity
1		Total protein	3
2	1	Hemoglobin	1
3	1	Anti-Escherichia coli (AEC)	3
4	1	(Nonspecific) IgM	3
5	1	(Nonspecific) IgG	3
6	1	Human anti-mouse antibody (HAMA)	1
7	1	Bilirubin	1
8	Endogenous Substance	Rheumatoid factors (RF)	3
9]	Anti-nuclear antibodies (ANA)	3
10]	Systemic Lupus Erythematosus (SLE)	13
11	1	Triglyceride	13
12	1	Cholesterol	10
13	1	Glucose	10
14	1	Uric acid	5
15	1	Multiple blood transfusions	5
16]	Pregnant women (multifarious)	20
17		Antiparasitic	1
18]	Antimalarial	1
19]	Antiretroviral	1
20	1	Anti-tuberculosis	1
21	Exogenous Substance	Aspirin	1
22]	Paracetamol	1
23]	Ibuprofen	1
24]	Alcohol	1
25]	Caffeine	1

2. Potential cross-reacting substances

The following listed 69 potentially cross-reacting substances have no impact on the test result of One Step Malaria (Pf/Pv) Tri-line Test. Although no cross reactivity in the study, the possibility cannot be completely excluded.

No.	Potential Cross-reacting Pathogen	Sample Quantity	No.	Potential Cross-reacting Pathogen	Sample Quantity
1	Hepatitis A virus (HAV)	3	36	Cryptococcus neoformans	1
2	Hepatitis C virus (HCV)	30	37	Rothia mucilaginosa	1
3	Hepatitis B virus (HBV)	26	38	Haemophilus influenzae	1
4	Human immunodeficiency virus (HIV)	14	39	Aspergillus fumigatus	1
5	Treponema pallidum (TP)	20	40	Aspergillus flavus	1
6	Influenza A (Flu A)	23	41	Streptococcus oralis	1
7	Influenza B (Flu B)	21	42	Streptococcus salivarius	1
8	Mycoplasmal pneumonia (MP)	3	43	Adenovirus type 1	1
9	Dengue	8	44	Adenovirus type 2	1
10	Mycobacterium tuberculosis (TB)	22	45	Adenovirus type 3	1
11	Toxoplasma (Toxo)	5	46	Adenovirus type 4	1
12	Measles virus	1	47	Adenovirus type 5	1
13	Varicella-zoster virus (VZV)	1	48	Adenovirus type 7	1
14	Epstein-Barr virus (EBV)	1	49	Adenovirus type 55	1
15	Mumps virus	1	50	Rhinovirus type B70	1
16	Streptococcus pneumonia type 14	1	51	Rhinovirus type A2	1
17	Staphylococcus aureus	1	52	Respiratory syncytial virus type A	1
18	Candida albicans	1	53	Respiratory syncytial virus type B	1
19	Human metapneumovirus	1	54	Herpes simplex virus	1
20	Bordetella pertussis	1	55	SARS coronavirus	10
21	Neisseria meningitidis	1	56	MERS coronavirus	1

4

22	Human cytomegalovirus	1	57	Schistosomiasis	2
		-			_
23	Norovirus	1	58	Leishmania	9
24	Bocavirus	1	59	Plasmodium malariae (Pm)	8
25	Chlamydia pneumoniae	1	60	Plasmodium ovale (Po)	3
26	Klebsiella pneumoniae	1	61	Rheumatoid factors	5
27	Neisseria gonorrhoeae	1	62	Anti-nuclear antibodies	5
28	Pyogenic streptococcus	1	63	Upper respiratory track infection (URTL)	14
29	Corynebacterium ulcerans	1	64	Respiratory track infection (UTI)	8
30	Legionella pneumophila	1	65	Tonsilitis	1
31	Staphylococcus epidermidis	1	66	Dental caries	1
32	Lactobacillus casei	1	67	Diarrhoea	3
33	Moraxella catarrhalis	1	68	Enteric fever	2
34	Escherichia coli	1	69	Pneumonia	3
35	Pseudomonas aeruginosa	1			

3. Hook effect

The hook effect was evaluated by testing dilution series prepared by clinical samples of high parasite densities up to 113,820 parasites/ μ L for Pf and 20,400 parasites/ μ L for Pv, whereas high antigen concentrations up to 68,496.720 ng/mL for Pf and 248.076 ng/mL for Pv. No hook effect was observed in the test results. Still, hook effect cannot be completely excluded especially when parasite density/antigen concentration is higher than the above values.

4. Diagnostic sensitivity & specificity

External clinical evaluations were conducted in four different sites located in Africa, Asia. Overall, a total of 1929 clinical samples (fingerstick/venous whole blood) were tested by One Step Malaria (Pf/Pv) Tri-line Test, with samples characterized by composite reference method, first by microscopy and further confirmed by PCR. Among these samples, 589 were malaria Pf positive, 167 malaria Pv positive, 3 malaria Pf & APv positive, 1170 malaria negative. The diagnostic sensitivity and specificity achieved from the studies are listed in tables below.

After 7 invalid sample results were excluded from the final analysis: Clinical sensitivity for Malaria Pf/Pv: 96.69% (95% Cl: 95.16%-97.75%) Clinical specificity for Malaria Pf/Pv: 98.89% (95% Cl: 98.10%-99.35%)

Table 2 Diagnostic Sensitivity study in four sites

Study site	Total number of malaria specimens tested	Specimen type	Number of specimens reactive by PCR and microscopy	Number of invalid tested	Number of specimens reactive by InTec RDT	Number of specimens falsely- nonreac- tive	Sensitivity	95% CI
Fingerstick v	whole blood							
Tanzania	383	Pf	383	0	366	17	95.56%	93.01%-97.21%
Venous who	le blood							
		Pf	81	0	79	2	97.53%	91.44%-99.32%
Ethiopia	176	Pv	92	3	86	3	96.63%	90.55%-98.85%
		Pf & Pv	3	0	3	0	100.00%	43.85%-100.00%
		Pf	100	0	98	2	98.00%	93.00%-99.45%
Bangladesh	150	Pv	50	0	49	1	98.00%	89.51%-99.65%
		Pf	25	0	25	0	100.00%	86.68%-100.00%
China	50	Pv	25	0	25	0	100.00%	86.68%-100.00%
Based on above data:								
			Total number	Number of invalid tested	Number of specimens reactive by InTec RDT	Number of specimens falsely- nonreactive	Overall sensitivity	95% CI
	Total		759	3	731	25	96.69%	95.16%-97.75%

Table 3 Diagnostic Specificity study in four sites

	Table 3 Diagnostic Specificity study in four sites							
Study site	Total number of malaria specimens tested	Specimen type	Number of specimens non-reactive by PCR and microscopy	Number of invalid tested	Number of specimens non-reactive by InTec RDT	Number of specimens falsely-re- active	Specificity	95% CI
Fingerstick	whole blood							
Tanzania	533	Pf	533	1	521	11	97.93%	96.34%-98.84%
Venous who	le blood							
		Pf	189	3	186	0	100.00%	97.98%-100.00%
Ethiopia	270	Pv	178	0	177	1	99.44%	96.89%-99.90%
		Pf & Pv	97	0	97	0	100.00%	96.19%-100.00%
		Pf	175	0	175	0	100.00%	97.85%-100.00%
Bangladesh	275	Pv	225	0	224	1	99.56%	97.53%-99.92%
		Pf & Pv	125	0	124	1	99.20%	95.61%-99.86%
China	0.2	Pf	67	0	67	0	100.00%	94.08%-100.00%
China	92	Pv	67	0	67	0	100.00%	94.08%-100.00%
				5				

	Pf & Pv	42	0	42	0	100.00%	91.62%-100.00%
Based on above data:							
		Total number	Number of invalid tested	Number of specimens non-reactive by InTec RDT	Number of specimens falsely- reactive	Overall specificity	95% CI
Total		1170	4	1153	13	98.89%	98.10%-99.35%

5. Analytical sensitivity (Limit of detection)

The limit of detection for Malaria Pf is 50 parasites/ μ L and for Malaria Pv is 133 parasites/ μ L according to the level of parasite based on calibration with reference materials.

6. Blood type equivalence study

The equivalence of testing different blood types was investigated and the study results demonstrated no significant difference among fingerstick blood and venous blood preserved in common anticoagulants EDTA, heparin sodium and sodium citrate.

7. Precision

The repeatability and reproducibility of One Step Malaria (Pf/Pv) Tri-line Test has been evaluated by within-run, between-run, between sites, between days, between operators and between lots studies using in-house control samples. The study results indicated 100% repeatability and 100% reproducibility.

Limitations A

- The kit is designed to detect malaria Pf antigen and/or Pv antigen in human whole blood. Specimens other than those specified may not supply accurate results and the device will not notify this kind of misuse to the user.
- The intensity of test band does not necessarily correlate to the titer of antigen in specimen.
- · The presence of the control band only indicates the flow of the conjugate.
- When a specimen contain high concentration of malaria is tested on the device, the control band could be absent due to the test principle.
- As this product is intended to detect Pf HRP-II and Pv pLDH antigens from individuals, clinical diagnosis should also be correlated with clinical presentations and epidemiological data.
- A negative result should not exclude the possibility of infection caused by Pf and/or Pv. A negative result can also occur in the following circumstances:
- Recently acquired Pf and/or Pv infection.
- Low levels of antigen below the detection limit of the test.
- Pf antigen and/or Pv antigen in the patient that do not react with specific antigens utilized in the assay configuration, in exceptional cases this may lead to observation of negative results.
- Specimens are not properly stored.
- High concentrations of particular analytes.
- Recently discovered sub-strain of Pf and/or Pv.
- Samples with Pf HRP-II/III gene deletions.
- For reasons above, care should be taken in interpreting negative results. Other clinical data (e.g., symptoms or risk factors) should be used in conjunction with the test results.
- Avoid using clotted or excessively viscous specimens.
- The product may give a false positive result even after the patient was treated for malaria several weeks before testing. The test cannot be used to monitor treatment response to antimalarials.

References

- 1. World Health Organization. Global Malaria Programme. https://www.who.int/teams/global-malaria-programme/case-management/diagnosis.
- 2. Quintana M, Piper R, Boling H L, et al. Malaria diagnosis by dipstick assay in a Honduran population with coendemic Plasmodium falciparum and Plasmodium vivax[J]. The American journal of tropical medicine and hygiene, 1998, 59(6): 868-871.
- Murray C K, Bennett J W. Rapid diagnosis of malaria[J]. Interdisciplinary Perspectives on Infectious Diseases, 2009, 2009.
- 4. Moody A. Rapid diagnostic tests for malaria parasites[J]. Clinical microbiology reviews, 2002, 15(1): 66-78.

Symbols

.,											
\triangle	CAUTION	Ť	KEEP DRY	(2)	DO NOT REUSE						
漛	KEEP AWAY FROM SUNLIGHT	X	TEMPERATURE LIMITATION	ī	CONSULT INSTRUCTIONS FOR USE						
	MANUEACTURED										
	MANUFACTURER	IVD	IVD						IN VITRO DIAGNOSTIC	<u>\</u>	CONTAINS SUFFICIENT
				MEDICAL DEVICE	Σ _N	FOR (N) TESTS					
LOT	BATCH CODE										
		DEE									
(🐼)	DO NOT USE IF PACKAGE IS DAMAGED	REF	CATALOGUE NUMBER	\geq	USE-BY DATE						
\checkmark	DAMAGED										



Tel: +86 592 6807188 Website: www.intecasi.com Email: intecproducts@asintec.com